Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Syncona (SYNC) Share News

IN BRIEF: Syncona says net asset value slips 1% in first quarter

10th Aug 2023 09:33

Syncona Ltd - London-based healthcare investor - Net asset value at June 30 is 184.6 pence per share, down 1.0% from 186.5p on March 31. NAV total return also was negative 1.0% for the recent three months, Syncona's financial first quarter. Notes performance was hurt by "negative foreign exchange movements" across its life science portfolio. This is valued at GBP628.7 million on June 30, up 4.0% from GBP604.6 million on March 31. Read More

IN BRIEF: Syncona's portfolio Achilles Therapeutics net loss narrows

4th Aug 2023 14:09

Syncona Ltd - Healthcare company focused on developing its life science portfolio - Notes its portfolio company Archilles Therapeutics PLC's net loss in its second quarter ended June 30 narrows 2.9% to USD16.8 million, from USD17.3 million year-on-year. Cash and cash equivalents are "strong", standing at USD143.7 million on June 30, down 17% from USD173.3 million on December 31. Research & development expenses increase are USD13.8 million, down 6.8% from USD14.8 million at the same point the year prior. Archilles Therapeutics's general & administrative expenses were USD4.3 million, down 26% from USD5.8 million the year before, driven by a change in cost allocations and lower professional fees. Read More

UK shareholder meetings calendar - next 7 days

25th Jul 2023 15:47

Syncona net asset value falls as cites economic uncertainty, inflation

15th Jun 2023 08:44

(Alliance News) - Syncona Ltd on Thursday reported a lower net asset value per share at the end of March amid a "challenging" backdrop for the biotechnology companies, citing inflation and economic uncertainty. Read More

LONDON BRIEFING: Stocks set lower after US Fed decision, ahead of ECB

15th Jun 2023 07:55

(Alliance News) - Stocks in London were set to open lower on Thursday, after the US Federal Reserve paused its interest rate hikes but indicated that more will follow this year. Read More

Syncona launches new gene therapy company with GBP96 million funding

12th Jun 2023 08:44

(Alliance News) - Syncona Ltd on Monday said it launched Beacon Therapeutics Holdings Ltd, a new ophthalmic therapy company, to treat patients with retinal diseases. Read More

TOP NEWS: AstraZeneca hails deal with Quell; positive danicopan data

9th Jun 2023 09:11

(Alliance News) - AstraZeneca PLC on Friday reported positive phase 3 trial data for its oral drug danicopan and struck an agreement with London-based biopharma company Quell Therapeutics Ltd. Read More

LONDON BRIEFING: Network International agrees to GBP2.2 billion buyout

9th Jun 2023 07:55

(Alliance News) - Stocks in London were called to open higher on Friday, after a weak US jobless claims reading threw "cold water" over expectations for an interest rate hike by the Federal Reserve next week. Read More

UK earnings, trading statements calendar - next 7 days

8th Jun 2023 15:49

IN BRIEF: Syncona investee Freeline swings to first-quarter profit

30th May 2023 14:30

Syncona Ltd - London-based investor in healthcare companies - Reports first-quarter results of investee Freeline Therapeutics Holdings PLC. Freeline is a clinical-stage biotechnology company. Freeline swings to a pretax profit of USD1.2 million in the first quarter of 2023, from a pretax loss of USD27.0 million last year. Profit is boosted by a reduction in expenses. Research & development expenses narrow to USD11.0 million from USD20.0 million, and total operating expenses similarly decrease to USD20.1 million from USD28.1 million. Read More

Syncona say portfolio clinical company Achilles have widened losses

10th May 2023 16:33

(Alliance News) - Syncona Ltd on Wednesday said that its portfolio company Achilles Therapeutics PLC has made losses in the first quarter of 2023, with cash equivalents falling and expenses increasing. Read More

IN BRIEF: Syncona leads GBP22.5 million financing in Mosaic

4th Apr 2023 19:29

Syncona Ltd - healthcare company focused on a portfolio of global leaders in life science - Leads GBP22.5 million Series A financing in Mosaic Therapeutics, a Cambridge England-based oncology therapeutics company. Commits GBP16.5 million alongside investment from Cambridge Innovation Capital. Reports holding value in Mosaic is GBP7.3 million following the investment of the first tranche of the Series A commitment and, once all current commitments are invested, will have a 52.8% stake in the business. Mosaic becomes Syncona's 13th company in its current portfolio. Read More

FTSE 100 Latest

Value9,068.58

Change-64.23